Piper Affirms Inovio Pharma (INO) at 'Overweight' Amid Increasingly Visible Clinical Progress

August 8, 2016 11:31 AM EDT
Get Alerts INO Hot Sheet
Price: $7.08 +3.21%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade INO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Piper Jaffray affirms Inovio Pharma (NASDAQ: INO) with an Overweight rating and $31 price target following Q2 results reported earlier Monday.

Analyst Charles Duncan summarized: Today Inovio reported 2Q16 financials, ending the quarter with $134.5M in cash. We project this cash will fund pipeline progress through 1H18, inclusive of significant progress on the soon-to-start Phase III in cervical dysplasia and advancement to late-stage trials for a broadening set of infectious disease and oncology programs including Zika, MERS, cervical cancer (with MedImmune), and potentially other tumors. Next up in 2016, our focus is on CD Phase III study design details, which we anticipate to be risk-reduced by similarities to the successful Phase IIb and to increase visibility on the path (time, capital requirements) to market for this lead program. We could also see 4Q value creation by data from Inovio’s Phase I, but high-profile Zika program, as well as Phase I’s in MERS, prostate and H&N cancer. In advance of increasingly visible clinical progress expected across the platform over the next 12 months, we reiterate OW.

For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment